<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>FOLFOX or FOLFIRI are commonly used as first- or second-line chemotherapy for unresectable <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> or its <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>.Recently, it had become a trend to add bevacizumab or cetuximab(Cmab)limited to the K-ras <z:mp ids='MP_0002169'>wild-type</z:mp> or panitumumab(Pmab)limited to the K-ras <z:mp ids='MP_0002169'>wild-type</z:mp>.At the present time, a common third-line chemotherapy is <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 plus Cmab limited to the K-ras <z:mp ids='MP_0002169'>wild-type</z:mp>, or Cmab/Pmab.However, the results are unsatisfactory.With Cmab plus S-1 we treated a case of remnant <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> from <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> which was a K-ras <z:mp ids='MP_0002169'>wild-type</z:mp>, after treating 5-FU, L-OHP and <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> marker dropped and 7 focuses of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> disappeared after 6 courses of treatment(complete response: CR in)and CR was achieved after 9 courses treatment.After 10 courses of treatment, a new lesion appeared on S5 of the liver and we performed percutaneous radiofrequency ablation </plain></SENT>
</text></document>